biostudies-literatureKadirkamanathan RRCUK | MRC | Medical Research FoundationMedical Research CouncilNational Institute for Health Research (NIHR)Wellcome TrustDeutsche Krebshilfe (German Cancer Aid)2978-2987https://www.ebi.ac.uk/biostudies/studies/S-EPMC12634419biostudies-literatureUnknown39(12)Acute myeloid leukaemia (AML) is often aggressive and life-threatening with limited curative options. Immunotherapies including chimeric antigen receptor (CAR) T-cell approaches are under investigation, but high levels of disease heterogeneity remain a major hurdle to achieving durable responses. Targeting of multiple antigens may ensure complete immunological coverage of leukaemic blast populations, but such antigens are often also present on healthy haematopoietic populations. To address likely aplasia, strategies can be designed to bridge CAR T-cell therapies to allogeneic stem-cell transplantation (allo-SCT), as demonstrated in recent anti-CD7 CAR T-cell studies. Here we report that monotherapy using base edited "universal" donor CAR T cells against CD33, CLL-1, or CD7 delivered inhibiLeukemiaBase edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia.PMC12634419MR/V03961X/1RP-2014-05-00770114706MR/X004619/1215619/Z/19/ZMRF-045-0003-RG-GEOR-C0907Heuser MEtuk AGeorgiadis CKadirkamanathan RGough OSchambach ASauer MQasim WKloos AJoshi APreece RfalseBase edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia.Acute myeloid leukaemia (AML) is often aggressive and life-threatening with limited curative options. Immunotherapies including chimeric antigen receptor (CAR) T-cell approaches are under investigation, but high levels of disease heterogeneity remain a major hurdle to achieving durable responses. Targeting of multiple antigens may ensure complete immunological coverage of leukaemic blast populations, but such antigens are often also present on healthy haematopoietic populations. To address likely aplasia, strategies can be designed to bridge CAR T-cell therapies to allogeneic stem-cell transplantation (allo-SCT), as demonstrated in recent anti-CD7 CAR T-cell studies. Here we report that monotherapy using base edited "universal" donor CAR T cells against CD33, CLL-1, or CD7 delivered inhibi2025-01-01T00:00:00Z2025 Dec2026-06-06T06:39:26.517Z2026-06-06T03:06:44.846ZS-EPMC126344194103442410.1038/s41375-025-02720-5